Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients (VZVinOLTx)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00492739 |
Recruitment Status
:
Recruiting
First Posted
: June 27, 2007
Last Update Posted
: December 30, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Varicella is a vaccine-preventable disease, which can be severe in immunosuppressed children. Currently, the (live) vaccine is not recommended in pediatric orthotopic liver transplant recipients. Furthermore, protection due to naturally acquired immunity to VZV or post-immunization isn't well described in this population.The questions asked are:
- What is the influence of the immunosuppression required after orthotopic liver transplantation (OLT) on the maintenance of VZV-specific immunity elicited by wild-type varicella infection before OLT transplantation?
- What is the influence of the immunosuppression required after OLT on VZV-specific immunity elicited by varicella immunization before OLT transplantation?
- What is the influence of the residual immunosuppression at ≥ 12 months after OLT transplantation on the induction of VZV-specific B and T cell responses elicited by VZV vaccination after OLT transplantation?
- What is the influence of the residual immunosuppression at ≥ 12 months after OLT transplantation on the persistence / waning of B and T cell responses elicited by VZV vaccination?
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Liver Disease Immunosuppression Varicella | Biological: Vaccination with VZV vaccine | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 80 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Induction and Maintenance of Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients: a Retrospective and Prospective Nationwide Study in Switzerland |
Study Start Date : | June 2007 |
Estimated Primary Completion Date : | April 2017 |
Estimated Study Completion Date : | December 2017 |

Arm | Intervention/treatment |
---|---|
Varicella vaccine
2-3 doses of Varicella vaccine to seronegative patients two months apart
|
Biological: Vaccination with VZV vaccine
Varicella vaccination 2 doses 2 months apart.
Other Name: Varilrix
|
- Safety of VZV vaccine in OLTx recipients [ Time Frame: 2 years ]
- Efficacy of VZV vaccine in immunosuppressed OLTx recipients [ Time Frame: 3 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Children either awaiting or recipients of a liver transplantation followed at the Children's Hospital of Geneva, Switzerland
- If vaccination offered: > 12 months of age
Exclusion Criteria:
- Known wild type varicella exposure within four weeks of the initial vaccine
- Immunoglobulins administered within the 5 months preceding the receipt of varicella vaccine.
- Antiviral agents administered during the preceding 4 weeks
- Febrile illness (>38.5°) in the 72 hours before vaccine administration
- Chronic aspirin therapy
- Any other live vaccinations within four weeks of receipt of varicella vaccine
- Female patients in childbearing age will have a pregnancy test at enrollment, and at the time of the second vaccine.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00492739
Contact: Klara M Posfay-Barbe, MD, MS | +41 22 372 5462 | Klara.PosfayBarbe@hcuge.ch | |
Contact: Valerie McLin, MD | +41 22 3723311 | Valerie.McLin@hcuge.ch |
Switzerland | |
Children's Hospital of Geneva (HUG) | Recruiting |
Geneva, GE, Switzerland, 1211 | |
Contact: Klara M Posfay-Barbe, MD, MS +41 22 372 5462 Klara.PosfayBarbe@hcuge.ch | |
Contact: Valerie McLin, MD +41 22 372 3311 Valerie.McLin@hcuge.ch | |
Principal Investigator: Klara M Posfay-Barbe, MD, MS |
Principal Investigator: | Klara M Posfay-Barbe, MD, MS | University Hospitals of Geneva |
Responsible Party: | Klara M. Pósfay Barbe, Head of Pediatric Infectious Diseases, University Hospital, Geneva |
ClinicalTrials.gov Identifier: | NCT00492739 History of Changes |
Other Study ID Numbers: |
VZVinOLTx |
First Posted: | June 27, 2007 Key Record Dates |
Last Update Posted: | December 30, 2016 |
Last Verified: | December 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Keywords provided by Klara M. Pósfay Barbe, University Hospital, Geneva:
Orthotopic liver transplantation Pediatric Immunosuppression Varicella vaccine B cell response |
T cell response Antibodies Varicella Chickenpox transplantation |
Additional relevant MeSH terms:
Liver Diseases Chickenpox Herpes Zoster Digestive System Diseases Herpesviridae Infections |
DNA Virus Infections Virus Diseases Vaccines Immunologic Factors Physiological Effects of Drugs |